{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.metaviatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Heon Kim  Hyung", "age": 47, "title": "CEO, President & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 716404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 66, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 565684, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. W. Christopher Fang M.D.", "title": "Consulting Chief Medical Officer & Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.54, "open": 1.6059, "dayLow": 1.5201, "dayHigh": 1.65, "regularMarketPreviousClose": 1.54, "regularMarketOpen": 1.6059, "regularMarketDayLow": 1.5201, "regularMarketDayHigh": 1.65, "payoutRatio": 0.0, "beta": 0.272, "volume": 13826, "regularMarketVolume": 13826, "averageVolume": 34925, "averageVolume10days": 20770, "averageDailyVolume10Day": 20770, "bid": 1.84, "ask": 3.2, "bidSize": 1, "askSize": 1, "marketCap": 13631421, "fiftyTwoWeekLow": 1.29, "fiftyTwoWeekHigh": 5.3, "fiftyDayAverage": 1.64738, "twoHundredDayAverage": 2.79003, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -2265581, "forwardPE": -0.5769231, "profitMargins": 0.0, "floatShares": 2339757, "sharesOutstanding": 8654870, "sharesShort": 50788, "sharesShortPriorMonth": 49120, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0058999998, "heldPercentInsiders": 0.631, "heldPercentInstitutions": 0.10484, "shortRatio": 1.9, "shortPercentOfFloat": 0.015700001, "impliedSharesOutstanding": 8654870, "bookValue": 0.918, "priceToBook": 1.7156863, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -27592000, "trailingEps": -3.56, "lastSplitFactor": "1:8", "lastSplitDate": 1703116800, "enterpriseToEbitda": 0.079, "52WeekChange": -0.59511566, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.575, "targetHighPrice": 23.0, "targetLowPrice": 6.0, "targetMeanPrice": 15.0, "targetMedianPrice": 15.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 16033000, "totalCashPerShare": 1.852, "ebitda": -28789000, "totalDebt": 136000, "quickRatio": 1.938, "currentRatio": 1.943, "debtToEquity": 1.715, "returnOnAssets": -0.9224, "returnOnEquity": -2.24179, "freeCashflow": -15156625, "operatingCashflow": -24710000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MTVA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470403800000, "marketState": "PRE", "regularMarketChangePercent": 2.272733, "regularMarketPrice": 1.575, "shortName": "MetaVia Inc.", "longName": "MetaVia Inc.", "regularMarketChange": 0.035000086, "regularMarketDayRange": "1.5201 - 1.65", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 34925, "fiftyTwoWeekLowChange": 0.2850001, "fiftyTwoWeekLowChangePercent": 0.22093031, "fiftyTwoWeekRange": "1.29 - 5.3", "fiftyTwoWeekHighChange": -3.7250001, "fiftyTwoWeekHighChangePercent": -0.7028302, "fiftyTwoWeekChangePercent": -59.511566, "dividendDate": 1577750400, "earningsTimestamp": 1742470263, "earningsTimestampStart": 1746621000, "earningsTimestampEnd": 1747053000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.56, "epsCurrentYear": -2.61, "priceEpsCurrentYear": -0.60344833, "fiftyDayAverageChange": -0.07237995, "fiftyDayAverageChangePercent": -0.0439364, "twoHundredDayAverageChange": -1.21503, "twoHundredDayAverageChangePercent": -0.43548992, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroBo Pharmaceuticals, Inc.", "nameChangeDate": "2025-04-01", "averageAnalystRating": "1.7 - Buy", "corporateActions": [], "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "MetaVia", "trailingPegRatio": null}